Top line accelerating.
+19.9% YoY versus +17.6% prior. 3y CAGR +16.5%.
+19.9%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $69.7B
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
2 of 2 legendary models say BUY BSX.
What would legendary investors pay for BSX?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Concerns — Boston Scientific Corporation's 13.7% ROE is below sector median.
Financial story
Concerns — Boston Scientific Corporation's 13.7% ROE and 0.71 debt-to-equity warrant a closer look at the underlying business.
Bottom line: BSX is rated BUY by 1 of 2 legendary models, with 1 holding and 0 flagging it overvalued, but earns a C sector grade (56/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
2 of 2 legendary investor models rate BSX a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $79. See the per-investor fair-value table in the valuation tab.
BSX trades at 22.7x earnings. Sector context and per-investor signals are in the valuation tab.
BSX and CI differ on P/E, ROE, and revenue growth. See the full BSX vs CI compare matrix.
Buffett and Lynch evaluate BSX against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
BSX's P/E ratio is 22.7x. 5-year P/E history is in the financials tab
+19.9% YoY versus +17.6% prior. 3y CAGR +16.5%.
+19.9%Net margin 14.4% versus 11.1% prior (+3.3pp). Operating 19.8%.
14.4%P/E 20.4x — 69% below the 5y median of 66.7x. Forward 13.5x hints at EPS expansion next year.
20.4xHow does BSX compare?
See exactly where BSX ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingBSX sits at #29 in Healthcare with a C grade (56/100).